Startups
Enterome
https://enterome.comCutting-edge immunomodulatory drugs for the treatment of cancer and immune diseases.
Summary
Industry
Insights
Enterome's focus on immunomodulatory drugs positions it well in the health and biopharma sectors, particularly in cancer and immune diseases. Based in Paris and operating on a B2B model, the company leverages research in immune system modulation to develop treatments that may complement existing therapies like chemotherapy and immunotherapies. Its specialized approach offers a competitive edge, potentially leading to more effective treatments, faster recovery times, and improved survival rates. Backed by investors such as The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Nestlé Health Science, Enterome shows strong market confidence and strategic support, enhancing its growth prospects in the biotech landscape.
Total Funding
$127M
- Series A (2012) $8.2M
- Series C (2016) $15.9M
- Series F (2023) $3.2M
- Series E (2020-01-01) $52.1M
- Series D (2017-01-01) $34.8M
- Series B (2014-01-01) $12.0M
- Seed (2011-01-01) $1.6M
Investors
Omnes Capital Series A
Omnes Capital Series A
Seventure Partners Series A
Nestlé Health Science Series C
The Leukemia & Lymphoma Society’s Therapy Acceleration Program Series F
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable